By targeting the tumor-associated microvasculature, antiangiogenic drugs – especially blocking signaling downstream of vascular endothelial growth factor (VEGF)/VEGF receptors – cause vessel pruning, which is followed by hypoxia and reduced supply of other nutrients (5–8). The gene discussed is VEGFA; the disease is neoplasm.